



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034.
Phone:040-23547532, Email : investors@natcopharma.co.in
CIN : L24230TG1981PLC003201 www.natcopharma.co.in

Extract of Unaudited Consolidated Financial Results for the Quarter and Half Year ended September 30, 2021

(All amounts in ₹ millions except per share data)

Sl. No.	Particulars	Quarter Ended		Half Year Ended		Year Ended
		30/09/2021 (Unaudited)	30/09/2020 (Unaudited)	30/09/2021 (Unaudited)	30/09/2020 (Unaudited)	31/03/2021 (Audited)
1	Revenue from operations	3,772	8,022	7,875	13,656	20,521
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	698	2,707	1,608	4,288	5,796
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	698	2,707	1,608	4,288	5,796
4	Net Profit for the period after tax (after exceptional and/or extraordinary items) and non-controlling interests	651	2,024	1,401	3,252	4,409
5	Total Comprehensive Income for the period attributable to owners of the parent	583	1,979	1,401	3,228	4,496
6	Paid-up Equity share capital of ₹2 each	365	364	365	364	365
7	Other equity (Revaluation reserve ₹ Nil)	-	-	-	-	40,851
8	Earnings Per Share (in Rupees) per ₹2/- share (non-annualised)					
	1) Basic	3.57	11.12	7.68	17.86	24.20
	2) Diluted	3.57	11.09	7.67	17.81	24.16

Notes:

1. Summarized Unaudited Standalone Financial Results of the Company is as under:

Sl. No.	Particulars	Quarter Ended		Half Year Ended		Year Ended
		30/09/2021 (Unaudited)	30/09/2020 (Unaudited)	30/09/2021 (Unaudited)	30/09/2020 (Unaudited)	31/03/2021 (Audited)
1	Revenue from operations	3,304	4,789	7,242	10,111	16,535
2	Profit before tax	523	865	1,433	2,481	3,922
3	Net profit for the period/ year	536	709	1,288	1,976	3,095
4	Total comprehensive income	513	770	1,352	2,042	3,228

2. The above is an extract of the detailed format of Financial Results for the quarter and half year ended 30 September, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly Financial Results are available on the Stock Exchange(s) websites: www.nseindia.com and www.bseindia.com and on the Company's website www.natcopharma.co.in
3. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on **November, 11, 2021**.
4. The Board of Directors at their meeting held on November 11, 2021 have recommended an interim dividend of ₹ 0.50 per equity share of ₹2 each.

Place: Hyderabad
Date: November, 11, 2021

for NATCO Pharma Limited
Sd/- V.C. Nannapaneni
Chairman & Managing Director



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034.

Phone:040-23547532, Email : investors@natcopharma.co.in

CIN : L24230TG1981PLC003201 www.natcopharma.co.in

Extract of Unaudited Consolidated Financial Results for the Quarter and Half Year ended September 30, 2021

(All amounts in ₹ millions except per share data)

Sl. No.	Particulars	Quarter Ended		Half Year Ended		Year Ended
		30/09/2021 (Unaudited)	30/09/2020 (Unaudited)	30/09/2021 (Unaudited)	30/09/2020 (Unaudited)	31/03/2021 (Audited)
1	Revenue from operations	3,772	8,022	7,875	13,656	20,521
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	698	2,707	1,608	4,288	5,796
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	698	2,707	1,608	4,288	5,796
4	Net Profit for the period after tax (after exceptional and/or extraordinary items) and non-controlling interests	651	2,024	1,401	3,252	4,409
5	Total Comprehensive Income for the period attributable to owners of the parent	583	1,979	1,401	3,228	4,496
6	Paid-up Equity share capital of ₹2 each	365	364	365	364	365
7	Other equity (Revaluation reserve ₹ Nil)	-	-	-	-	40,851
8	Earnings Per Share (in Rupees) per ₹2/- share (non-annualised)					
	1) Basic	3.57	11.12	7.68	17.86	24.20
	2) Diluted	3.57	11.09	7.67	17.81	24.16

Notes:

1. Summarized Unaudited Standalone Financial Results of the Company is as under:

Sl. No.	Particulars	Quarter Ended		Half Year Ended		Year Ended
		30/09/2021 (Unaudited)	30/09/2020 (Unaudited)	30/09/2021 (Unaudited)	30/09/2020 (Unaudited)	31/03/2021 (Audited)
1	Revenue from operations	3,304	4,789	7,242	10,111	16,535
2	Profit before tax	523	865	1,433	2,481	3,922
3	Net profit for the period/ year	536	709	1,288	1,976	3,095
4	Total comprehensive income	513	770	1,352	2,042	3,228

2. The above is an extract of the detailed format of Financial Results for the quarter and half year ended 30 September, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly Financial Results are available on the Stock Exchange(s) websites: www.nseindia.com and www.bseindia.com and on the Company's website www.natcopharma.co.in
3. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on **November, 11, 2021**.
4. The Board of Directors at their meeting held on November 11, 2021 have recommended an interim dividend of ₹ 0.50 per equity share of ₹2 each.

for NATCO Pharma Limited
Sd/- V.C. Nannapaneni
Chairman & Managing Director

Place: Hyderabad

Date: November, 11, 2021

Place: Hyderabad Date: 12/11/2021
Sd/- Authorized Officer, P. O. of M. E. Home Film

Business Standard 12/11/2021



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad - 500 034.
CIN : L24230TG1981PLC003201 www.natcopharma.co.in

NOTICE

DECLARATION OF 2nd INTERIM DIVIDEND AND RECORD DATE

The Company hereby informs that the Board of Directors at their meeting held on 11th November 2021 declared an Interim Dividend of Rs.0.50 (25%) per equity Share of Rs.2/- each of the Company. The Interim Dividend will be paid to the shareholders of the Company whose name appear in the Register of Members of the Company or in the records of the Depositories as beneficial owners of the said shares as on **24th November, 2021**, being the Record Date fixed for the purpose. The payment of said Interim dividend will be start from 1st December, 2021.

For **NATCO Pharma Limited**

Sd/- **M. Adinarayana**

Company Secretary & Vice President
(Legal & Corporate Affairs)

Place : Hyderabad

Date : 11-11-2021